Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 29, 2026
Principal Office: San Diego, California
Trading Symbol: CAPR (Nasdaq Global Select Market)
This filing reports a significant regulatory event regarding the Company's lead product candidate, Deramiocel, intended for the treatment of cardiomyopathy in patients with Duchenne muscular dystrophy (DMD).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statements or performance metrics.
Material Changes and Events
- FDA Advisory Committee Vote: On July 29, 2026, the FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted that available evidence did not support the effectiveness of Deramiocel for the treatment of cardiomyopathy in DMD patients.
- Vote Breakdown: 3 votes for, 9 votes against, 0 abstentions.
- Regulatory Status: The Advisory Committee's recommendation is non-binding. The FDA will consider this recommendation alongside the complete administrative record during its ongoing review of the Biologics License Application (BLA).
- Timeline: The FDA's Prescription Drug User Fee Act (PDUFA) target action date for the BLA remains August 22, 2026.
Outlook, Risks, and Management Commentary
Management Commentary: The Company issued a press release on July 30, 2026, announcing the Advisory Committee vote. The filing notes that DMD is a rare, life-threatening disease with no currently approved cardiomyopathy treatment.
Risks and Contingencies:
- Regulatory Risk: Despite the negative advisory vote, the final FDA decision is not yet made. The outcome of the BLA review remains uncertain pending the FDA's final action on August 22, 2026.
- Market Impact: The negative vote suggests significant hurdles to approval, which could materially impact the Company's future prospects and stock price.
Investor Verification Checklist
- Verify the final FDA decision on the Deramiocel BLA expected by August 22, 2026.
- Review the full text of the press release (Exhibit 99.1) for additional management commentary on the vote.
- Monitor subsequent filings for any updates on the Company's cash position and runway given the potential impact of a non-approval.
- Assess the Company's pipeline for alternative candidates if Deramiocel is not approved.